|
Status |
Public on Mar 30, 2022 |
Title |
A genome-wide CRISPR activation screen identifies PRRX2 as a regulator of enzalutamide resistance in prostate cancer |
Organism |
Homo sapiens |
Experiment type |
Expression profiling by high throughput sequencing Genome binding/occupancy profiling by high throughput sequencing
|
Summary |
This SuperSeries is composed of the SubSeries listed below.
|
|
|
Overall design |
Refer to individual Series
|
|
|
Citation missing |
Has this study been published? Please login to update or notify GEO. |
|
Submission date |
Mar 28, 2022 |
Last update date |
Apr 01, 2022 |
Contact name |
Sarki Abdulkadir |
E-mail(s) |
sarki.abdulkadir@northwestern.edu
|
Organization name |
Northwestern University
|
Street address |
303 E Superior St
|
City |
Chicago |
State/province |
IL |
ZIP/Postal code |
60611 |
Country |
USA |
|
|
Platforms (2) |
GPL18573 |
Illumina NextSeq 500 (Homo sapiens) |
GPL20301 |
Illumina HiSeq 4000 (Homo sapiens) |
|
Samples (16)
|
|
This SuperSeries is composed of the following SubSeries: |
GSE199537 |
A genome-wide CRISPR activation screen identifies PRRX2 as a regulator of enzalutamide resistance in prostate cancer [ATAC-seq] |
GSE199538 |
A genome-wide CRISPR activation screen identifies PRRX2 as a regulator of enzalutamide resistance in prostate cancer [RNA-seq] |
|
Relations |
BioProject |
PRJNA820694 |